| Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline M Tuccori, S Ferraro, I Convertino, E Cappello, G Valdiserra, C Blandizzi, ... MAbs 12 (1), 1854149, 2020 | 139 | 2020 |
| The impact of the COVID-19 “Infodemic” on drug-utilization behaviors: implications for pharmacovigilance M Tuccori, I Convertino, S Ferraro, E Cappello, G Valdiserra, D Focosi, ... Drug safety 43, 699-709, 2020 | 89 | 2020 |
| Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients I Convertino, M Tuccori, S Ferraro, G Valdiserra, E Cappello, D Focosi, ... Critical Care 24, 1-6, 2020 | 51 | 2020 |
| Italian emergency department visits and hospitalizations for outpatients’ adverse drug events: 12-year active pharmacovigilance surveillance (The MEREAFaPS Study) N Lombardi, G Crescioli, A Bettiol, M Tuccori, A Capuano, R Bonaiuti, ... Frontiers in pharmacology 11, 412, 2020 | 34 | 2020 |
| The usefulness of listening social media for pharmacovigilance purposes: a systematic review I Convertino, S Ferraro, C Blandizzi, M Tuccori Expert opinion on drug safety 17 (11), 1081-1093, 2018 | 32 | 2018 |
| An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and … M Tuccori, I Convertino, S Ferraro, G Valdiserra, E Cappello, E Fini, ... Expert Opinion on Drug Discovery 16 (12), 1403-1414, 2021 | 18 | 2021 |
| Is there a risk of lymphoma associated with anti-tumor necrosis factor drugs in patients with inflammatory bowel disease? A systematic review of observational studies S Ferraro, L Leonardi, I Convertino, C Blandizzi, M Tuccori Frontiers in Pharmacology 10, 247, 2019 | 17 | 2019 |
| Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data F Cucchiara, S Ferraro, G Luci, G Bocci Pharmacological Research 175, 105976, 2022 | 12 | 2022 |
| Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis I Convertino, S Salvadori, A Pecori, MT Galiulo, S Ferraro, M Parrilli, ... Drug Safety 42, 427-444, 2019 | 11 | 2019 |
| Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non … I Convertino, E Lucenteforte, R Gini, V Lorenzoni, M Cazzato, G Turchetti, ... Clinical and Experimental Rheumatology 39 (4), 753-762, 2020 | 10 | 2020 |
| Olfactory and gustatory impairments in COVID‐19 patients: Role in early diagnosis and interferences by concomitant drugs S Ferraro, M Tuccori, I Convertino, G Valdiserra, E Cappello, F Maggi, ... British journal of clinical pharmacology 87 (5), 2186-2188, 2021 | 6 | 2021 |
| Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance S Ferraro, I Convertino, L Leonardi, C Blandizzi, M Tuccori Expert Opinion on Drug Safety 18 (12), 1245-1253, 2019 | 6 | 2019 |
| Anti‐SARS‐CoV‐2 neutralizing monoclonal antibodies: clinical pipeline. mAbs. 2020; 12: 1854149 M Tuccori, S Ferraro, I Convertino, E Cappello, G Valdiserra, C Blandizzi, ... | 6 | |
| Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. mAbs. 2020; 12 (1): 1854149 M Tuccori, S Ferraro, I Convertino, E Cappello, G Valdiserra, C Blandizzi Epub 2020/12/16. https://doi. org/10.1080/19420862.2020. 1854149 PMID: 33319649, 0 | 6 | |
| Tixagevimab+ cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence I Convertino, S Ferraro, E Cappello, G Valdiserra, M Bonaso, M Tuccori Expert Opinion on Drug Discovery 18 (3), 231-245, 2023 | 5 | 2023 |
| Preclinical discovery and development of the casirivimab+ imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall M Tuccori, I Convertino, S Ferraro, E Cappello, G Valdiserra, G de Luca, ... Expert Opinion on Drug Discovery 17 (6), 531-546, 2022 | 5 | 2022 |
| Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. mAbs 12: 1854149 M Tuccori, S Ferraro, I Convertino, E Cappello, G Valdiserra, C Blandizzi, ... | 5 | 2020 |
| Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases I Convertino, M Cazzato, S Giometto, R Gini, G Valdiserra, E Cappello, ... Scientific Reports 11 (1), 20314, 2021 | 4 | 2021 |
| Trajectories of adherence to biologic disease-modifying anti-rheumatic drugs in tuscan administrative databases: The pathfinder study I Convertino, S Giometto, R Gini, M Cazzato, M Fornili, G Valdiserra, ... Journal of Clinical Medicine 10 (24), 5743, 2021 | 3 | 2021 |
| Cases of acquired hemophilia A following COVID‐19 vaccines: Cogent safety signal or possible reporting/detection bias? Preliminary evidence from Tuscany, Italy G Roberto, O Paoletti, S Ferraro, G Hyeraci, M Franchini, R Gini, D Focosi, ... Pharmacoepidemiology and Drug Safety 32 (6), 694-699, 2023 | 2 | 2023 |
